CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Korsana Biosciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Korsana Biosciences, Inc.
245 First Street, 18th Floor
Phone: (857) 327-8778p:857 327-8778 CAMBRIDGE, MA  02142  United States Ticker: KRSAKRSA
This company was Merged or Acquired on 9/8/2026.
This is a Subsidiary, click here for the Parent Company
Business Summary
Korsana Biosciences, Inc., formerly Cyclerion Therapeutics, Inc., is a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. The Company's lead program, KRSA-028, is a next-generation shuttle antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, it is advancing a pipeline of innovative therapies for neurodegenerative diseases.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board TomasKiselak 40 9/8/2026 9/8/2026
President, Chief Executive Officer, Director JonathanViolin 50 9/8/2026 9/8/2026
Chief Financial Officer Mark J.Vignola 49 9/8/2026 9/8/2026
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Cyclerion GmbH
Cyclerion Securities Corporation
CYCN
CYCNV
KRSA

General Information
Number of Employees: 1 (As of 6/30/2026)
Outstanding Shares: 45,541,358 (As of 10/15/2026)
Shareholders: 70
Stock Exchange: NASD
Federal Tax Id: 831895370


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, October 25, 2026